BACKGROUND: The incidence of symptomatic venous thromboembolism (VTE) following hematopoietic stem cell transplantation (HSCT) is not well described, particularly with increased use of ambulatory care in the transplant setting. METHODS: A retrospective analysis involving 589 patients (382 autologous HSCT, 207 allogeneic HSCT) undergoing transplantation between 2000 and 2005 in a single Canadian institution was undertaken to identify the incidence of proximal deep vein thrombosis (DVT) or pulmonary embolism (PE) in HSCT patients. RESULTS: The total 1-year incidence of symptomatic VTE was 3.7% [95% confidence interval (CI) 2.5-5.6]. Among the HSCT patients, 7/589 (1.2%, 95% CI 0.6-2.4) developed symptomatic non-catheter-related VTE following HSCT (four PE and three DVT). All VTE events occurred after hematopoietic engraftment. Patients undergoing autologous HSCT did not receive thromboprophylaxis, whereas most patients undergoing allogeneic HSCT (79.7%) received enoxaparin 20 mg daily for the prevention of veno-occlusive disease of the liver, starting 6 +/- 3 days before transplantation for a mean of 22 +/- 14 days. CONCLUSION: HSCT patients have a high incidence of VTE. Thromboprophylaxis should potentially be considered in these patients. However, future studies assessing the risk and benefits of thromboprophylaxis are needed in this specific population.
BACKGROUND: The incidence of symptomatic venous thromboembolism (VTE) following hematopoietic stem cell transplantation (HSCT) is not well described, particularly with increased use of ambulatory care in the transplant setting. METHODS: A retrospective analysis involving 589 patients (382 autologous HSCT, 207 allogeneic HSCT) undergoing transplantation between 2000 and 2005 in a single Canadian institution was undertaken to identify the incidence of proximal deep vein thrombosis (DVT) or pulmonary embolism (PE) in HSCT patients. RESULTS: The total 1-year incidence of symptomatic VTE was 3.7% [95% confidence interval (CI) 2.5-5.6]. Among the HSCT patients, 7/589 (1.2%, 95% CI 0.6-2.4) developed symptomatic non-catheter-related VTE following HSCT (four PE and three DVT). All VTE events occurred after hematopoietic engraftment. Patients undergoing autologous HSCT did not receive thromboprophylaxis, whereas most patients undergoing allogeneic HSCT (79.7%) received enoxaparin 20 mg daily for the prevention of veno-occlusive disease of the liver, starting 6 +/- 3 days before transplantation for a mean of 22 +/- 14 days. CONCLUSION: HSCT patients have a high incidence of VTE. Thromboprophylaxis should potentially be considered in these patients. However, future studies assessing the risk and benefits of thromboprophylaxis are needed in this specific population.
Authors: Kylee L Martens; Wilson L da Costa; Christopher I Amos; Chris Davis; Madeline Kesten; Stephanie J Lee; Neil A Zakai; David A Garcia; Ang Li Journal: Blood Adv Date: 2021-01-12
Authors: Jorge Labrador; Lucia Lopez-Anglada; Estefania Perez-Lopez; Francisco S Lozano; Lucia Lopez-Corral; Fermin M Sanchez-Guijo; Lourdes Vazquez; Jose Angel Perez Rivera; Francisco Martin-Herrero; Mercedes Sanchez-Barba; Carmen Guerrero; Maria Consuelo del Cañizo; Maria Dolores Caballero; Jesus Fernando San Miguel; Ignacio Alberca; Jose Ramon Gonzalez-Porras Journal: Haematologica Date: 2012-08-16 Impact factor: 9.941
Authors: Nicholas S Wilcox; Seth J Rotz; McKay Mullen; Evelyn J Song; Betty Ky Hamilton; Javid Moslehi; Saro H Armenian; Joseph C Wu; June-Wha Rhee; Bonnie Ky Journal: Circ Res Date: 2022-02-17 Impact factor: 17.367
Authors: Amer M Zeidan; Jessica Wellman; Patrick M Forde; Javier Bolaños-Meade; Michael B Streiff Journal: J Thromb Thrombolysis Date: 2014-05 Impact factor: 2.300
Authors: A Richters; M van Vliet; P G M Peer; P E Verweij; B A P Laros-van Gorkom; N M A Blijlevens; J P Donnelly; W J F M van der Velden Journal: Bone Marrow Transplant Date: 2013-11-04 Impact factor: 5.483
Authors: Johannes Dillmann; Felix C Popp; Barbara Fillenberg; Florian Zeman; Elke Eggenhofer; Stefan Farkas; Marcus N Scherer; Michael Koller; Edward K Geissler; Robert Deans; Deborah Ladenheim; Martin Loss; Hans J Schlitt; Marc H Dahlke Journal: Trials Date: 2012-11-15 Impact factor: 2.279